ALK and non-small cell lung carcinoma: Ultimately, our study results serve as a platform for further clinical research on new-generation ALKIs as first-line therapies for advanced ALK-positive NSCLC patients of Asian ethnicity and not as direct evidence to establish any single agent as a frontline option at present.